Glycemic Management in CKM and CKD - Nephrology Lectures 2025

HbA1c does two jobs in CKM, and does both badly in CKD. It defines stages 1 and 2 as a threshold, then stops mattering to staging entirely. And in the population nephrology actually sees, the assay it depends on becomes progressively less trustworthy exactly as the stakes rise.

🔢 Problem 1 — HbA1c is a switch, not a dial

CKM staging treats diabetes as binary. An HbA1c of 6.5% assigns stage 2. An HbA1c of 13% also assigns stage 2. Severity never escalates the stage.

Same stage, different disease. A 55-year-old with an HbA1c of 6.6% on metformin and a 55-year-old with an HbA1c of 13%, osmotic symptoms and catabolic weight loss are both CKM stage 2. Nothing in the stage label distinguishes them.

Severity re-enters in two places, both outside the stage:

Agent selection. "Severe hyperglycemia" is named among the comorbidities steering the choice of cardioprotective antihyperglycemic, and uncontrolled diabetes favors a GLP-1 RA over finerenone in the albuminuria add-on decision.
PREVENT. The guideline states that the PREVENT equations have "add-on models incorporating UACR, HbA1c, and the social deprivation index" — so HbA1c is carried as a continuous input there. If you stage without running an add-on PREVENT model, that risk simply disappears from the assessment.

Where glycemic severity does change management

Not through the CKM stage, but through the ADA Standards of Care. These are the verified triggers:

ADA Standards of Care in Diabetes — 2026, Section 9 (Pharmacologic Approaches to Glycemic Treatment). Verified against the section text.
Trigger	Action
A1C at or above 1.5% above the individualized goal	Many individuals will require dual-combination therapy or a more potent glucose-lowering agent to reach and hold goal
A1C above 10% (above 86 mmol/mol), or blood glucose at or above 300 mg/dL (16.7 mmol/L), or symptoms of hyperglycemia	Consider initiating insulin regardless of background glucose-lowering therapy or disease duration (Recommendation 9.20, grade E)
Severe hyperglycemia with catabolic features — weight loss, hypertriglyceridemia, ketosis	Insulin should be considered as part of any combination plan
No severe hyperglycemia or hyperglycemic crisis	GLP-1-based therapy is preferred to insulin for initial or add-on therapy (Recommendation 9.21, grade A)
If insulin is used	Combination with a GLP-1 RA, including a dual GIP and GLP-1 RA, is recommended (Recommendation 9.22)

Note that the first trigger is relative, not absolute. It is not "an A1C of 8%" — it is 1.5% above that patient's individualized goal. For a CKD patient whose goal sits at the loose end of the KDIGO range, that arithmetic lands in a very different place than it does for a patient with a goal below 6.5%.

🧪 Problem 2 — the assay degrades as CKD advances

Reliability and targets by G stage, per KDIGO 2022. Verified against the peer-reviewed synopsis of the guideline (Ann Intern Med. 2023;176(3):381–387), which reproduces all recommendations and practice points verbatim.
G stage	Reliability	Target
G1–G2	Reliable	Individualized, below 6.5% to below 8.0%
G3a–G3b	Generally reliable	Same range — the guideline sets one target for all non-dialysis CKD and does not tighten it by G stage
G4–G5, not on dialysis	Accuracy and precision decline	Same range, interpreted with caution; in practice most patients sit at the loose end
G5D (dialysis)	Low reliability	KDIGO sets no HbA1c target here

The dialysis carve-out is explicit, and it is easy to miss. KDIGO Recommendation 2.2.1 reads, verbatim: "We recommend an individualized HbA1c target ranging from <6.5% to <8.0% in patients with diabetes and CKD not treated with dialysis (1C)." The range does not extend to G5D. KDIGO deliberately declines to set a dialysis target — because the biomarker it would be measured with is the one Practice Point 2.1.2 calls low-reliability in exactly that population. Circular, and the guideline knows it. For a patient on dialysis, index glycemia with CGM metrics — time in range, time in hypoglycemia — and treat any HbA1c as an estimate, not a goal.

Neither the target nor the monitoring interval is stratified by G stage. Practice Point 2.1.1 sets one schedule for everyone with diabetes and CKD: twice per year is reasonable, rising to as often as four times per year if the target is not met or after a change in glucose-lowering therapy. The interval is a function of control and therapy changes, not of eGFR band. Where a patient sits inside the 6.5–8.0% range is likewise a function of hypoglycemia risk, comorbidity and life expectancy — not G stage.

🧬 Why HbA1c misreads in CKD — the mechanisms

Pushes it falsely LOW

Shortened erythrocyte survival — less time to glycate
ESA-driven reticulocytosis — a young red cell population
Transfusion
Hemolysis

These dominate in advanced CKD.

Pushes it falsely HIGH

Iron deficiency — an aged red cell population
Metabolic acidosis
Carbamylation interference in uremia (assay-dependent)

Partially offsetting, and unpredictably so in the individual patient.

Net effect: in CKD, HbA1c usually reads falsely low. The practical consequence is that the guideline's "0.5–1% above goal" metformin trigger becomes unreliable below an eGFR of 30 — which is also, conveniently, where metformin is contraindicated.

Why not just use a different marker?

KDIGO retains HbA1c as the biomarker of choice even in advanced CKD (Recommendation 2.1.1, 1C). Glycated albumin and fructosamine carry their own assay biases in the setting of hypoalbuminemia — common with proteinuria, malnutrition and peritoneal dialysis. When HbA1c is discordant with measured glucose or with clinical symptoms, the guideline directs you to the CGM-derived glucose management indicator (GMI) rather than to an alternative glycated protein.

⚠️ Nephrology-specific glycemic traps

Euglycemic DKA

Relative insulinopenia plus an SGLT2 inhibitor is the classic setup. At HbA1c above 10% with catabolic features, establish insulin before or alongside the SGLT2i.

AKI in the uncontrolled band

Sustained hyperglycemia drives osmotic diuresis and glomerular hyperfiltration — volume depletion, AKI and an accelerated eGFR slope, independent of the assigned stage.

Glycemic efficacy falls with eGFR

SGLT2i retains cardiorenal benefit down to eGFR 20 but is not a glucose-lowering agent at G4. Do not let the cardiorenal indication substitute for glycemic control.

Dosing floors

Metformin contraindicated below eGFR 30. SGLT2i initiable to eGFR 20. Finerenone requires potassium surveillance. GLP-1 RA dosing is not eGFR-adjusted.

🔗 Where to go next

🧬 Staging and the kidney axis ⚖️ CKM staging vs KFRE

🔍 Source and verification

Primary source: the 2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome (Circulation. 2026;154(4):e50–e158, PMID 42263157), published Free Access and read in full for these pages. Glycemic triggers are from the ADA Standards of Care in Diabetes — 2026, Section 9 (PMID 41358900), read in full via PubMed Central. Kidney staging and glycemic targets in CKD are from KDIGO 2024 and KDIGO 2022 (PMID 36272764), the latter verified against its peer-reviewed synopsis (PMID 36623286).

Every numeric threshold on this page was checked against the source text. Figures that could not be confirmed in a primary source were removed rather than published with a caveat — including a set of pre-HF biomarker cut points that circulate in secondary summaries but appear nowhere in the guideline.

🧪 Glycemic Management in CKM and CKD